Growth headlines hide margin cuts and JV drag — first order cancellation in 15 years

The headline is bright: revenue of ₹180 Cr surged 81.5% year-on-year, and net profit jumped 754% to ₹9.6 Cr. But Q1 is just 10–15% of JNK's annual revenue — it's a seasonally small quarter — and the YoY base was depressed (₹99 Cr prior year). The real story sits underneath: management cut full-year revenue growth guidance from 25–30% to 20–25%, trimmed EBITDA margin guidance from 14–15% to 12–14%, and revealed that a consolidated EBITDA margin of 11.8% — 220 basis points below its standalone 14% — was dragged down by a ₹3.6 Cr operating loss in the Chemdist joint venture.

The YoY surge is real in absolute terms — revenue grew from ₹99 Cr to ₹180 Cr — but the jump is amplified by a particularly weak prior-year quarter. Margins tell the story: the company achieved a 14% standalone EBITDA margin, which matches guidance, and net profit margin recovered to 5.2% from 1.1% a year earlier. The recovery is genuine. But consolidated profit was dragged by Chemdist (green hydrogen and sustainable fuels JV that contributed 8.8% of group revenue at ₹16 Cr but incurred an operating loss of ₹3.6 Cr). Management expects this to turn profitable by year-end, citing operating leverage as the JV scales revenue. The company also moved to input-based revenue recognition (from output-based), which pulled forward ₹210 Cr of unbilled revenue — a legitimate accounting change that signals forward visibility but also means some Q2–Q4 revenue is already on the books.

The stock opened to a -2.85% drop on day 1 post-result, recovered to +8.84% by day 3, and held that pop at +10.68% by day 5. The market initially punished the guidance cuts and JV losses, but the strong order book and expanded pipeline persuaded buyers back in. The bounce has stuck: the stock now trades at ₹463.95, up from a 52-week low of ₹200.92 (+130.91% off the low) but down 16.85% from its all-time high of ₹558. Technically, it's above its 20-day average (₹441.4) but below its 50-day average (₹471.25) and well above its 200-day average (₹322.33); RSI at 51.5 signals equilibrium, not overbought.

Institutional flows tell a different story. FII ownership has fallen sharply to 0.94% from 1.17% in the prior quarter — a 23 basis point exit in one quarter — suggesting foreign investors are reducing exposure. DII ownership slipped to 10.92% from 12.56% (-164 bps), indicating domestic institutions are also trimming. Promoters remain locked in at 67.79%, showing no insider selling. Bulk deals in early June 2026 showed mixed activity in the ₹496–499 range, with no evidence of promoter-linked selling near the all-time high. The ownership shift is a red flag: while the market bounced on fundamentals, smart money is walking away.

Consolidated EBITDA margin in Q2 and beyond. If the Chemdist loss shrinks materially and margin approaches the 12–14% guidance range without further guidance cuts, the quarter's caution was justified. If margin stays at 11–12% or slides further, the diversification and JV strategy is hitting headwinds and the cuts were only the start. At ₹463.95 (trading near the 20-day average), the stock is neither rich nor cheap — fair value hinges on whether margins stabilize at guidance or deteriorate further.